Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Study finds higher free iron content in dark beer

A team of researchers from the University of Valladolid has analysed 40 brands of beer, discovering that dark beer has more free iron than pale and non-alcoholic beers. Iron is essential to the human diet, but also helps oxidise the organic compounds that give these beverages stability and flavour.

11 Aug 2011

Althea hosts Health and Wellness Fair for employees

Althea Technologies, Inc., a leading provider of development and manufacturing services for biotechnology and pharmaceutical companies, held its inaugural Health and Wellness Fair today.

11 Aug 2011

FDA approves Gilead's Complera for treatment of HIV-1 infection

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Complera, a complete single-tablet regimen for the treatment of HIV-1 infection in treatment-naïve adults.

11 Aug 2011

Once daily HIV ‘combo’ drug approved in U.S.

The U.S. Food and Drug Administration (FDA) has given its approval to a once daily HIV treatment that combines Gilead Sciences Inc.'s drug Truvada with Johnson & Johnson's drug Edurant, Gilead said Wednesday.

11 Aug 2011

NCI, Genesis Biopharma sign CRADA agreement to develop cancer immunotherapies

Genesis Biopharma, Inc., a biotechnology company developing targeted cancer immunotherapies, today announced it has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute.

10 Aug 2011

Protox reports net loss of $3.2 million for second quarter 2011

Protox Therapeutics Inc., a developer of innovative products for the treatment of urological diseases, today announced financial results and achievements for the quarter ended June 30, 2011.

10 Aug 2011

Akela announces new corporate focus on PharmaForm

Akela Pharma, Inc. today announced a new strategic focus on its profitable pharmaceutical contract manufacturing business, PharmaForm, LLC.

9 Aug 2011

Simcere second quarter total revenue increases 0.3% to US$84.4 million

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today reported preliminary unaudited financial results for the quarter ended June 30, 2011.

9 Aug 2011

Exactech's new Optetrak Logic knee implant effective for painful arthritis

Kevin Hindle, a 47-year-old manufacturing engineer at Exactech, Inc., a global orthopaedic device company, regained his active lifestyle with an innovative new knee implant that he helped develop.

9 Aug 2011

Gilead to acquire Genentech's OCP facility, other process development assets

Gilead Sciences, Inc. today announced that the company has signed a definitive agreement under which Gilead will purchase a clinical biologics manufacturing facility and certain process development assets located in Oceanside, California from Genentech, a member of the Roche Group.

9 Aug 2011

K-V sells assets of Nesher to Zydus and Zynesher Pharmaceuticals

K-V Pharmaceutical Company today announced the completion and closing of the previously announced sale of assets of Nesher Pharmaceuticals, Inc., the Company's wholly-owned generic subsidiary, and the Company's generic business and assets to Zydus Pharmaceuticals (USA), Inc and Zynesher Pharmaceuticals (USA) LLC.

9 Aug 2011

AMRI second quarter total revenue increases 9% to $53.9 million

AMRI today reported financial and operating results for the second quarter ended June 30, 2011.

8 Aug 2011

Masimo lifts voluntary product recall of Pronto-7 noninvasive finger sensor

Masimo announced today that it has lifted the voluntary product recall the company imposed on the noninvasive finger sensor of its Pronto-7 handheld device to improve the product's performance in low ambient temperatures. The Pronto-7 and new finger sensors are pending FDA 510(k) clearance in the U.S.

8 Aug 2011

Inhibitex second quarter net loss decreases to $5.3 million

Inhibitex, Inc. today announced its financial results for the second quarter ended June 30, 2011 and provided an update on several recent clinical and corporate developments.

8 Aug 2011

Unigene second quarter revenue decreases to $2.5 million

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced second quarter financial results for the period ended June 30, 2011. The Company highlighted significant progress achieved in the second quarter with the continued execution of its turnaround strategy.

8 Aug 2011